Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

NCT: NCT03796559 · RECRUITING

NCT IDNCT03796559
StatusRECRUITING
Start Date2019-06-13
Completion2027-05
SponsorEndomagnetics Ltd. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.

Frequently Asked Questions

What is Magseed Enabled Long-Term Localization of Axillary Lymph Nodes?

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes is a clinical trial registered under NCT03796559. Current status: RECRUITING.

What is the status of NCT03796559?

The current status of NCT03796559 (Magseed Enabled Long-Term Localization of Axillary Lymph Nodes) is: RECRUITING.

When did Magseed Enabled Long-Term Localization of Axillary Lymph Nodes start?

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes started on 2019-06-13.

Related Devices

PMA P160053Lymph node location system during sentinel biopsy procedureEndomagnetics Ltd., K153044Sentimag System, Sentimark Magnetic Marker SystermEndomagnetics Ltd., K163541Magseed Magnetic Marker SystemEndomagnetics Ltd., K173587Magseed Magnetic Marker SysttemEndomagnetics Ltd., K222832Sentimag SystemEndomagnetics Ltd.,

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑